Baxter (NYSE:BAX) announced today that data shows the potential for machine learning supporting decision-making with infusion pump programming. Deerfield, Illinois-based Baxter presented the data from a retrospective study — part of a collaboration with MedAware aimed to develop next-generation dose error reduction software — at the American Society of Health-System Pharmacists (ASHP) 2021 Midyear Clinical […]
Technology
Bigfoot Biomedical touts cloud-based program for managing diabetes
Bigfoot Biomedical officials think their Bigfoot Unity diabetes management program and Bigfoot Clinic Hub could up the game in the space. Milpitas, California-based Bigfoot designed the Bigfoot Unity platform to allow healthcare professionals (HCPs) to review patient data. The information comes from the patient’s prescribed Bigfoot Unity system, integrating with Abbott’s FreeStyle Libre 2 continuous […]
Better Therapeutics completes enrollment in type 2 diabetes study
Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes. San Francisco-based Better Therapeutics’ BT-001 prescription digital therapeutic delivers a novel cognitive-behavioral therapy to patients with uncontrolled type 2 diabetes. According to a news release, the trial for BT-001 exceeded its enrollment target, bringing in 662 […]
Better Therapeutics closes SPAC merger, debuts on Nasdaq
Better Therapeutics announced today that it completed its merger with Mountain Crest Acquisition Corp and has gone public on the Nasdaq. San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. Last month, the company confirmed its expectations for the $113 million SPAC merger to […]
LifeScan launches digital diabetes management platform
LifeScan announced today that it launched its OneTouch solutions offering wellness programs to help people manage their diabetes. Malvern, Pennsylvania-based LifeScan made its OneTouch solutions available to consumers in the U.S. now and plans to soon offer it to healthcare providers, payors and employers as a reimbursed adjudicated option in early 2022. OneTouch solutions connects […]
Ultrahuman hires chief business officer as it scales expansion for glucose monitoring tech
Metabolic tracking technology developer Ultrahuman announced today that it appointed Bhuvan Srinivasan as its first chief chief business officer. The appointment of Srinivasan to the new role follows Bangalore, India-based Ultrahuman’s $17.5 million Series B financing round completed in August. Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes […]
Massachusetts offers Medicaid coverage for Pear Therapeutics’ digital therapeutics
Pear Therapeutics announced today that MassHealth intends to cover the company’s prescription digital therapeutics (PDTs). MassHealth, Massachusetts’ Medicaid program, notified Pear of its plans to cover the FDA-authorized reSET and reSET-O PDTs for treating substance use disorder and opioid use disorder, respectively. The decision remains subject to certain customary conditions, including federal and state approvals as […]
Dexcom announces Garmin as first partner for real-time APIs
Dexcom (NYSE:DXCM) announced today that Garmin introduced its Dexcom Connect IQ apps on its smartwatch and cycling computer. Garmin today launched the apps to provide people using the Dexcom G7 continuous glucose monitor (CGM) with Type 1 and Type 2 diabetes a way to quickly see glucose levels and trends, even while working out. Apps […]
Metabolic disease reversal tech company Twin Health raises $140M Series C
Twin Health announced that it raised $140 million in a Series C financing round as it scales its service in the U.S. and globally. Mountain View, California-based Twin Health develops the Whole Body Digital Twin platform designed to help reverse and prevent chronic metabolic diseases while improving energy and health. According to a news release, […]
Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings
Merck & Co. (NSDQ:MRNA) scientists have explored fighting cancer by way of the STING (stimulator of interferon genes)-controlled innate immune pathway. Now, the company has published research in Advanced Therapeutics detailing a preclinical study with its partner Vesselon Inc. that reported impressive pharmacokinetics results related to MSA-1, a STING agonist. The researchers found that low […]
